---
title: "Prime Medicine says FDA clears IND for PM577a in Wilson disease trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293661316.md"
description: "Prime Medicine received FDA clearance for its Investigational New Drug (IND) application for PM577a, an in vivo prime editor targeting H1069Q-mutated Wilson disease. This approval facilitates a global Phase 1/2 clinical program, with trial initiation planned for the second half of 2026 and initial clinical data expected in 2027."
datetime: "2026-07-23T20:13:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293661316.md)
  - [en](https://longbridge.com/en/news/293661316.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293661316.md)
generator: "portal-rs"
---

# Prime Medicine says FDA clears IND for PM577a in Wilson disease trial

-   Prime Medicine won FDA clearance of its IND for PM577a, an in vivo prime editor targeting H1069Q-mutated Wilson disease. \* The decision enables a global Phase 1⁄2 program with its previously cleared New Zealand CTA. \* Trial start is slated for H2 2026; initial clinical data are expected in 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607231605PRIMZONEFULLFEED9767379) on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [PRME.US](https://longbridge.com/en/quote/PRME.US.md)

## Related News & Research

- [Chardan Capital Reaffirms Their Buy Rating on Prime Medicine, Inc. (PRME)](https://longbridge.com/en/news/296873445.md)
- [Prime Medicine Maintained at Buy with Unchanged $6 Price Target on Emerging Program Clarity and 2027 Catalysts](https://longbridge.com/en/news/296139179.md)
- [Belite Bio to present Phase 3 DRAGON tinlarebant results in Stargardt disease at SOG congress](https://longbridge.com/en/news/296615069.md)
- [Zevra Therapeutics presents long-term real-world MIPLYFFA data in Niemann-Pick type C at SSIEM 2026](https://longbridge.com/en/news/296905592.md)
- [AC Immune reports positive interim Phase 1 data for NLRP3 inhibitor ACI-19764](https://longbridge.com/en/news/296478492.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**